Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer

Oxaliplatin is widely used in the frontline treatment of colorectal cancer (CRC), but an estimated 50% of patients will eventually stop responding to treatment due to acquired resistance. This study revealed that diminished MEIS1 expression was detected in CRC and harmed the survival of CRC patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yimin, Gan, Yaqi, Liu, Jiaxin, Li, Juanni, Zhou, Zhengwei, Tian, Ruotong, Sun, Ruizheng, Liu, Jiaqi, Xiao, Qing, Li, Yuanyuan, Lu, Pengyan, Peng, Yulong, Peng, Yuqian, Shu, Guang, Yin, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964798/
https://www.ncbi.nlm.nih.gov/pubmed/35351858
http://dx.doi.org/10.1038/s41392-022-00902-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964798/
https://www.ncbi.nlm.nih.gov/pubmed/35351858
http://dx.doi.org/10.1038/s41392-022-00902-6

Ejemplares similares